HCM
ICPT

Highbridge Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Highbridge Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-233,100
Closed -$3.79M – 731
2022
Q1 		$3.79M Buy
+233,100
New +$3.65M 0.09% 274
2016
Q3 		– Sell
-20,000
Closed -$2.85M – 1755
2016
Q2 		$2.85M Buy
+20,000
New +$2.92M 0.05% 362

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Highbridge Capital Management's ICPT Position: Q1 2017 in Review

Highbridge Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2017, closing a stake of 5,605 shares — an estimated $609K sold.

Highbridge Capital Management first reported a position in ICPT in Q4 2014 and held it in 4 quarters. The position peaked at $5.81M in Q4 2014. 150 funds tracked by Wall St. Rank hold ICPT as of Q1 2017.

  • Highbridge Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 5,605 Intercept Pharmaceuticals, Inc. shares in Q1 2017, an estimated $609K.
  • Highbridge Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
  • Highbridge Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $5.81M in Q4 2014.
  • 150 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2017.

Based on Highbridge Capital Management's 13F filing for Q1 2017, filed 15 May 2017.